

Teva brings Generic Elidel Cream, 1% in US market

01 January 2019 | News

“We’re proud to offer another affordable treatment option. This launch represents an important addition to our generics portfolio and underscores our commitment to ensuring that patients have more treatment options.”



Teva Pharmaceutical Industries Ltd., today announced the launch of a generic version of Elidel[®]1 (pimecrolimus) Cream, 1% in the U.S.

Pimecrolimus Cream, 1% is a topical prescription medicine to be used as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adults and children 2 years of age and older who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.

Brendan O’Grady, EVP and Head of North America Commercial at Teva said, “We’re proud to offer another affordable treatment option. This launch represents an important addition to our generics portfolio and underscores our commitment to ensuring that patients have more treatment options.”

With over 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Elidel[®] Cream, 1% had annual sales of approximately \$218.4 million in the US, according to IQVIA data as of October 2018.